Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation

BCL-2 family proteins are frequently aberrantly expressed in mantle cell lymphoma (MCL). Recently, the BCL-2-specific inhibitor venetoclax has been approved by the US Food and Drug Administration for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). In MCL, venetoclax has shown pr...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Haematologica (Roma) Ročník 108; číslo 3; s. 797 - 810
Hlavní autori:	Thus, Yvonne J., De Rooij, Martin F.M., Swier, Nathalie, Beijersbergen, Roderick L., Guikema, Jeroen E.J., Kersten, Marie-José, Eldering, Eric, Pals, Steven T., Kater, Arnon P., Spaargaren, Marcel
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Italy Fondazione Ferrata Storti 01.03.2023 Ferrata Storti Foundation
Predmet:	Adult Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Bridged Bicyclo Compounds, Heterocyclic - pharmacology Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Casein Kinase II - genetics Casein Kinase II - metabolism Cell Line, Tumor Down-Regulation Humans Lymphoma, Mantle-Cell - drug therapy Lymphoma, Mantle-Cell - genetics Lymphoma, Mantle-Cell - metabolism Myeloid Cell Leukemia Sequence 1 Protein - metabolism Non-Hodgkin Lymphoma Proto-Oncogene Proteins c-bcl-2
ISSN:	0390-6078, 1592-8721, 1592-8721
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!